Conditions: Heart Failure
Keywords: omecamtiv mecarbil
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 35
Healthy volunteers: no

Brief summary:
This study is designed to understand the pharmacokinetics of different oral formulations of CK-1827452 being considered for future studies in patients with heart failure. This study will compare the pharmacokinetics and safety and tolerability of both modified-release (MR) and immediate-release (IR) oral formulations of CK-1827452.

Detailed description:

Arms:
arm 1: Modified-release (MR) 50 mg dose of CK-1827452 twice a day (BID) for 10 days. arm 2: Immediate-release (IR) 37.5 mg dose of CK-1827452 three times a day (TID) for 10 days. arm 3: Modified-release (MR) 100 mg dose of CK-1827452 twice a day (BID) for 10 days

Interventions: intervention 1: CK-1827452 intervention 2: CK-1827452 intervention 3: CK-1827452
Intervention descriptions: intervention 1: 50 mg MR CK-1827452 BID for 10 days intervention 2: 37.5 mg IR CK-1827452 TID for 10 days intervention 3: 100 mg MR CK-1827452 BID for 10 days

Protocol document: